lovastatin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Del Gaudio, F; Guerrera, IC; Monti, MC; Riccio, R | 1 |
| Al-Ashmawy, GM; Amr, EA; El-Ashmawy, NE; Khedr, EG | 1 |
| Cao, Z; Chen, C; Dai, Z; Deng, X; He, G; Lin, L; Lu, L; Ouyang, W; Song, L; Tan, S; Tao, X; Wu, D; Yan, S; Yao, H; Yi, H; Zou, G | 1 |
| Bao, G; Chen, M; Dai, Z; Gao, C; Gong, Z; Krueger, CJ; Liang, X; Zhang, N; Zhou, Y | 1 |
| Chen, C; Deng, X; He, G; Rosol, TJ; Song, L; Yan, S; Yao, H | 1 |
| Bao, Y; Jiang, L; Jiang, X; Kou, X; Lin, Z; Ling, S; Liu, H; Qin, N; Sun, F; Yang, Y; Zhang, Z | 1 |
1 review(s) available for lovastatin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triple-negative breast cancer: is there a treatment on the horizon?
Topics: Anthracyclines; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Simvastatin; Taxoids; Triple Negative Breast Neoplasms | 2017 |
5 other study(ies) available for lovastatin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes.
Topics: Anticholesteremic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeleton; Female; Humans; Immunoblotting; Lovastatin; Mass Spectrometry; Phosphoproteins; Phosphorylation; Proteome; Proteomics; Signal Transduction; Triple Negative Breast Neoplasms | 2020 |
Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Chloroquine; Docosahexaenoic Acids; Female; Humans; Lovastatin; Transforming Growth Factor beta1; Triple Negative Breast Neoplasms | 2020 |
Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Humans; Lovastatin; Neoplastic Stem Cells; Triple Negative Breast Neoplasms | 2018 |
Loading Lovastatin into Camptothecin-Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Floxuridine; Humans; Lovastatin; Mice; Nanocapsules; Triple Negative Breast Neoplasms | 2018 |
Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Class III Phosphatidylinositol 3-Kinases; Female; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lovastatin; Lysosomes; Mice; Mice, Inbred BALB C; Mice, Nude; Panobinostat; Protein Serine-Threonine Kinases; rab GTP-Binding Proteins; rab7 GTP-Binding Proteins; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |